Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Acquired by Westhampton Capital LLC

Westhampton Capital LLC boosted its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 3.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,292 shares of the medical research company’s stock after purchasing an additional 75 shares during the quarter. Westhampton Capital LLC’s holdings in Thermo Fisher Scientific were worth $1,192,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in TMO. Busey Bank raised its position in Thermo Fisher Scientific by 3.6% during the fourth quarter. Busey Bank now owns 30,231 shares of the medical research company’s stock worth $15,727,000 after acquiring an additional 1,044 shares during the period. Synergy Asset Management LLC acquired a new position in shares of Thermo Fisher Scientific during the 4th quarter worth about $70,000. Strategic Planning Group LLC boosted its holdings in Thermo Fisher Scientific by 4.5% in the 4th quarter. Strategic Planning Group LLC now owns 6,615 shares of the medical research company’s stock worth $3,441,000 after buying an additional 286 shares during the last quarter. Highland Capital Management LLC raised its holdings in shares of Thermo Fisher Scientific by 10.0% during the fourth quarter. Highland Capital Management LLC now owns 33,979 shares of the medical research company’s stock valued at $17,677,000 after acquiring an additional 3,102 shares during the last quarter. Finally, Summa Corp. boosted its stake in shares of Thermo Fisher Scientific by 7.4% in the fourth quarter. Summa Corp. now owns 1,456 shares of the medical research company’s stock worth $757,000 after acquiring an additional 100 shares during the last quarter. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $558.12, for a total transaction of $5,581,200.00. Following the completion of the transaction, the chief executive officer now directly owns 33,608 shares of the company’s stock, valued at approximately $18,757,296.96. The trade was a 22.93 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders have sold a total of 34,850 shares of company stock worth $19,123,197 in the last quarter. 0.34% of the stock is owned by company insiders.

Thermo Fisher Scientific Trading Down 2.9 %

Shares of NYSE TMO opened at $567.09 on Thursday. The stock has a fifty day simple moving average of $536.74 and a 200-day simple moving average of $570.35. Thermo Fisher Scientific Inc. has a twelve month low of $493.30 and a twelve month high of $627.88. The company has a current ratio of 1.63, a quick ratio of 1.26 and a debt-to-equity ratio of 0.64. The stock has a market capitalization of $216.91 billion, a PE ratio of 35.55, a PEG ratio of 3.82 and a beta of 0.76.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Thursday, January 30th. The medical research company reported $6.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.48% and a return on equity of 17.49%. On average, equities analysts forecast that Thermo Fisher Scientific Inc. will post 21.69 earnings per share for the current year.

Thermo Fisher Scientific declared that its board has approved a stock repurchase program on Friday, November 15th that permits the company to buyback $4.00 billion in shares. This buyback authorization permits the medical research company to reacquire up to 2% of its stock through open market purchases. Stock buyback programs are often a sign that the company’s leadership believes its stock is undervalued.

Thermo Fisher Scientific Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, January 15th. Investors of record on Friday, December 13th were issued a $0.39 dividend. The ex-dividend date of this dividend was Friday, December 13th. This represents a $1.56 dividend on an annualized basis and a yield of 0.28%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 9.78%.

Analyst Ratings Changes

TMO has been the topic of a number of research reports. Redburn Atlantic assumed coverage on Thermo Fisher Scientific in a report on Monday, October 14th. They issued a “buy” rating and a $680.00 price objective on the stock. TD Cowen upped their price objective on shares of Thermo Fisher Scientific from $656.00 to $686.00 in a research note on Tuesday, October 22nd. Robert W. Baird decreased their target price on shares of Thermo Fisher Scientific from $632.00 to $622.00 and set an “outperform” rating on the stock in a research note on Thursday, October 24th. Evercore ISI cut their price target on Thermo Fisher Scientific from $630.00 to $620.00 and set an “outperform” rating for the company in a report on Thursday, October 24th. Finally, Scotiabank began coverage on Thermo Fisher Scientific in a research note on Monday, December 23rd. They set a “sector perform” rating and a $605.00 price objective on the stock. Four equities research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $648.95.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.